Agilent’s PD-L1 test gains FDA nod for ovarian cancer
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
Subscribe To Our Newsletter & Stay Updated